CClinicalTrials.gg
CompletedNCT05325996Updated Aug 20, 2026

Evaluating Home Testing Devices for the Management of Glaucoma

An interventional study of Standard Automatic Perimetry Humphrey Field Analyzer and visuALL H in Glaucoma, Open-Angle, sponsored by Wills Eye. Completed at 1 site in United States. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Wills Eye · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
20 Years to 80 Years
Sex
All
01

Study summary

With the advancement in technology we have the opportunity of performing the glaucoma testing at home to monitor the disease. The purpose of this study is evaluating the feasibility and patient acceptance of home testing with head mounted perimetry; detection of progression with head mounted perimetry vs office based perimetry; and monitoring the eye pressure measured by patients at home using a portable tonometer.

Read the detailed description

Standard Automatic Perimetry (SAP) is the gold standard test for evaluation of diseases of the visual pathway like glaucoma. Its main goal is to measure differential light sensitivity at several locations in the field of vision. Several devices have been developed since the advent of the Octopus Perimeter and the Humphrey Field Analyzer (HFA) is now the most commonly used machine for checking the visual field. These devices have a number of disadvantages including being stressful for debilitated, ill, or elderly patients to keep their heads still in the perimeter bowl during the test.

Recently, several methods have been introduced for checking the visual field using laptops or iPads. These modalities bring portability but lack fixation methods, environmental control, hardware standardization, and lack the ability of checking the visual acuity. These deficiencies may limit their wide usage. VisuALL is a Head Mounted perimeter that connects to its application on the cell phone or tablet via Bluetooth. In addition to being a portable perimeter and checking visual acuity, it has the ability of monitoring fixation with an accuracy of 1 degree. The measured visual field will be saved on a cloud space and available to the physician and patient. It has been shown that the more frequent visual tests we perform, the earlier we would be able to detect visual field progression. Currently, the visual field test is performed on patients in an ophthalmology clinic with a technician present during the test. The VisuALL has a demo video to provide education to the patient on the simple and user-friendly process of visual field testing.

Tonometry is the measurement of eye pressure. iCare Home Tonometer measurements have been shown to be highly correlated to Goldmann Tonometer measurements which are performed in the ophthalmic office. Multiple studies have highlighted the shortcomings of relatively infrequent in office tonometry. Recent studies have suggested that peak out of office eye pressures are often higher than in office pressures and the iCare Home Tonometer is one option to assess eye pressure outside of the office.

Home monitoring of glaucoma may present opportunities to reduce the burdens of office visits while increasing the monitoring of the visual field and eye pressure. This study is intended to assess the feasibility and utility of home based perimetry and tonometry in the management of glaucoma.

02

Conditions studied

  • Glaucoma, Open-Angle

Browse trials for

Keywords

  • Open Angle Glaucoma
  • Perimetery
  • Tonometry
  • Eye Pressure
  • Visual Field
  • Home Test
03

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age 20-80 years
  2. Mild and Moderate Open Angle Glaucoma (OAG)
  3. Refraction under 12.00 diopter of spherical refractive error and astigmatism of less than 2.5 diopter.

Exclusion criteria

Exclusion Criteria:

  1. Spherical refraction outside > ± 12.00 D and cylinder correction > +2.5 D.
  2. Visual acuity worse than 20/50 either eye
  3. Cataract surgery with or without Minimally Invasive Glaucoma Surgery (MIGS) less than 90 days prior to enrollment
  4. Filtering surgeries less than 6 months prior to enrollment
  5. Intraocular surgery other than:

    1. Non-complicated MIGS more than 90 days prior to enrollment;
    2. Cataract or refractive surgery performed more than 90 days before enrollment and without posterior capsule opacification
    3. Other glaucoma surgery more than 6 months prior to enrollment.
  6. History of systemic or ocular condition (other than glaucoma or mild to moderate cataract) known to affect visual function.
  7. History of medication known to affect visual function or influence patient reaction time
  8. Inability to use device after remote training session
  9. Subjects unwilling and/or unable to participate
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Moderate Glaucoma

    Subjects between ages 20-80 years with a diagnosis of mild and moderate Open Angle Glaucoma in at least one eye with 20/50 vision or better will be included in this study. All subjects will have the Olleyes Perimeter measure their own visual acuity and field once a week during a 2 year period and iCare home to measure their eye pressure 3 times a day for 7 days every 3 months during a 2 year period. All patient will have their routine glaucoma assessment with the standard 24-2 Automatic Perimetry Humphrey Field Analyzer at baseline and every 6 months during a 2 year period; and Spectralis Optical Coherence Tomography thickness of peripapillary RNFL and macular ganglion cell at baseline and yearly during a 2 year period.

    Diagnostic Test: Standard Automatic Perimetry Humphrey Field Analyzer · Diagnostic Test: visuALL H · Diagnostic Test: iCare Home Tonometer · Diagnostic Test: Spectralis Optical coherence tomography (OCT)

Interventions

  • Diagnostic testStandard Automatic Perimetry Humphrey Field Analyzer

    Standard Automatic Perimetry (SAP) using the Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures the visual field in an ophthalmic setting.

    Also known as: SAP HFA

  • Diagnostic testvisuALL H

    visuALL H a new portable perimeter measuring the visual field and acuity in a non ophthalmic setting.

  • Diagnostic testiCare Home Tonometer

    iCare HOME tonometer is a device developed for patients/subjects to measure their eye pressure at home.

  • Diagnostic testSpectralis Optical coherence tomography (OCT)

    Optical coherence tomography (OCT) is a computerized picture measuring the thickness of the inner layer of the retina that makes the optic nerve.

05

What researchers measure

Primary outcomes

  1. Change in Visual Field Mean Deviation with VisuALL

    The visual field measures sensitivity of the retina to light at several locations in the peripheral vision. The difference of mean of these measurements compared to a normal database is presented in negative or positive values called mean deviation. Visual field mean deviation (MD) (light measurement in decibels in multiple spots across the central and peripheral retina known as entire visual field) will be captured by VisuALL per eye once a week during a 2 year period at participant's home.

    Time frame: 12 minutes each week for 104 weeks

  2. Change in Intraocular Pressure with iCare

    Intraocular pressure, measured in millimeters of mercury (mmHG), will be measured by patients using a device called iCare Home Tonometer, specifically designed for patients to measure their eye pressures at home. They will measure eye pressure of each eye 3 times a day for 7 days every 3 months during a 2 year period at participant's home.

    Time frame: 15 minutes daily over 1 week, 8 times for 2 years

Secondary outcomes

  1. Change in Visual Field Mean Deviation with Humphrey Field Analyzer

    The visual field measures sensitivity of the retina to light at several locations in the peripheral vision. The difference of mean of these measurements compared to a normal database is presented in negative or positive values called mean deviation. Visual field mean deviation (MD) (light measurement in decibels in multiple spots across the central and peripheral retina known as entire visual field) will be measured in the office by Humphrey perimeter 24-2 SITA standard per 3 times at baseline and then every 6 months during a 2 year period..

    Time frame: 2 hours, 5 times for 2 years

Other outcomes

  1. Change in Retinal Nerve Fiber Layer (RNFL) Thickness

    Retinal Nerve Fiber Layer (RNFL) Thickness in microns will be obtained by a computerized picture without touching the eye with Spectralis (Zeiss) Optical Coherence Tomography (OCT) at baseline and then yearly during a 2 year period.

    Time frame: 10 minutes, 3 times for 2 years

06

Study locations

1 site
  • Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05325996
Lead sponsor
Wills Eye
Responsible party
M. Reza Razeghinejad MD (Principal Investigator, Wills Eye) — Principal investigator
First posted
Apr 13, 2022
Start date
Apr 15, 2022
Primary completion
Aug 17, 2026
Completion
Aug 17, 2026
Last update
Aug 20, 2026

Study contacts

M. Reza Razeghinejad, MD
principal investigator · Wills Eye Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion